| Name | Cefotaxime sodium |
| Description | Cefotaxime is a third-generation cephalosporin antibiotic. Like other third-generation cephalosporins, it has broad spectrum activity against Gram positive and Gram negative bacteria. In most cases, it is considered to be equivalent to ceftriaxone in terms of safety and efficacy. Cefotaxime sodium (Cefotaxim sodium salt) is marketed under various trade names including Claforan (Sanofi-Aventis). |
| In vitro | It has activity in presence of some beta-lactamases, both penicillinases and cephalosporinases of Gram negative and Gram positive bacteria. Its spectrum of activity includes most strains of bacterial pathogens responsible for septicaemia, respiratory tract infections, urinary tract infections, soft tissue infections, bone and joint infections, obstetric and gynaecological infections, and other various types of infections[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 50 mg/mL (104.73 mM), Sonication is recommended.
Ethanol : < 1 mg/mL (insoluble or slightly soluble)
|
| Keywords | PBPs | Inhibitor | inhibit | HR-756 | HR756 | HR 756 | Cefotaxime sodium | Cefotaxime | Cefotaxim sodium | Cefotaxim | Bacterial | Antibiotic |
| Inhibitors Related | Neomycin sulfate | Dehydroacetic acid sodium | Ampicillin sodium | Methyl anthranilate | Doxycycline (hyclate) | Kanamycin sulfate | Urethane | Sulfamethoxazole sodium | Doxycycline | EDTA copper(II) disodium salt | Isoeugenol | Dimethyl sulfoxide |
| Related Compound Libraries | FDA-Approved & Pharmacopeia Drug Library | Bioactive Compound Library | Approved Drug Library | ReFRAME Related Library | Drug-induced Liver Injury (DILI) Compound Library | Drug Repurposing Compound Library | FDA-Approved Drug Library | Immunology/Inflammation Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Covalent Inhibitor Library | Anti-COVID-19 Compound Library |
United States
